ABOUT   |   AIMS and SCOPE   |   AUTHOR INSTRUCTIONS   |   EDITORIAL BOARD   |   ARCHIVE   |   CURRENT ISSUE   |   SUBMIT MANUSCRIPT ONLINE  |

This Article

Copyright © 2012 | AIZEON publishers | All rights reserved

 Open Access
 Abstract Free
 Full Text PDF Free

 

Services

Articles by corresponding author in PubMed

Articles by corresponding author in Google Scholar

 

 

 

aizeon

 



 

ABSTRACT   REFERENCES  
Journal of Bioinformatics and Research 1(1) 2012: 10-14

Computational analysis of active site amino acid dihedral angles of CDK2 towards ligand binding


Srinivasu Nulaka1* and Appa Rao Allam2

1Department of Computer Science (MCA), KGRL College, Bhimavaram, AP, India. E-mail: nulaka@gmail.com
2Vice-chancellor, JNTUK, Kakinada, AP, India E-mail : apparaoallam@gmail.com

* To whom correspondence should be addressed. Email: nulaka@gmail.com

REFERENCES

  1. Brun V, Legraverend M, Grierson DS (2001). Cyclin-dependent kinase (CDK) inhibitors: development of a general strategy for the construction of 2,6,9-trisubstituted purine libraries. Part 1 Tetrahedron Lett . 42 : 8161-8164.
  2. Schang LM (2002). Cyclin-dependent kinases as cellular targets for antiviral drugs. J Antimicrob Chemother. 50 : 779-792.
  3. Fischer PM, Endicott J, Meijer L (2003). Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res. 5 :235-248.
  4. Sausville EA, Johnson J, Alley M et al (2000). Inhibition of CDKs as a therapeutic modality. Ann N Y Acad Sci. 910:207-221.
  5. Ekholm SV and Reed SI (2000). Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol. 12: 676-684.
  6. Endicott JA, Noble ME, Tucker JA (1999). Cyclin-dependent kinases: inhibition and substrate recognition. Curr Opin Struct Biol. 9: 738-744.
  7. Gartel AL, Tyner AL (2002). The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther . 1: 639-649.
  8. Sherr CJ (2000). The Pezcoller lecture: cancer cell cycles revisited. Cancer Res . 60: 3689-3695.
  9. http://www.cellsignal.com/reference/pathway/Cell_Cycle_G1S.html
  10. Noble ME, Endicott JA, Johnson LN (2004). Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-1806
  11. Canduri F and De Azevedo Jr WF (2005). Structural Basis for Interaction of Inhibitors with Cyclin-Dependent Kinase 2 Current Comput-Aided Drug Design. 1:53-64.
  12. Pindur U, Kim YS, Mehrabani F (1999). Advances in indolo[2,3-a]carbazole chemistry: design and synthesis of protein kinase C and topoisomerase I inhibitors. Curr Med Chem .6:29-69.
  13. Golbraikh A and Tropsha A (2002). Beware of q2! J. Mol. Graph. Model. 20: 269-276.
  14. Afantitis A, Melagraki G, Sarimveis H et al (2006). A Novel QSAR Model for Modeling and Predicting Induction of Apoptosis by 4-Aryl-4H-chromenes Bioorg. Med. Chem. 14: 6686-6694.
  15. Kim D, Hong SI, Lee DS (2006). The quantitative structure-mutagenicity relationship of polycylic aromatic hydrocarbon metabolites Mol. Sci. 7: 556-570.



Copyright © 2012 | AIZEON publishers | All rights reserved

..........................................................................................................................................................................................................

Citation: Nulaka S and Allam AR (2012). Computational analysis of active site amino acid dihedral angles of CDK2 towards ligand binding. Journal of Bioinformatics and Research 1(1): 10-14

..........................................................................................................................................................................................................

 

 

Template by JustDreamweaver.com